Biogen Inc. (NASDAQ:BIIB) Q4 2023 Earnings Conference Call February 13, 2024 8:00 AM ET Company Participants Chuck Triano - Head of Investor Relations Chris Viehbacher - President and Chief Executive Officer Priya Singhal - Head of Development Mike McDonnell - Chief Financial Officer Conference Call Participants Marc Goodman - Leerink Partners Salveen Richter - Goldman Sachs Umer Raffat - Evercore ISI Evan Seigerman - BMO Capital Markets Phil Nadeau - TD Cowen Michael Yee - Jefferies Colin Bristow - UBS Chr ...

Biogen (BIIB) reported fourth-quarter 2023 adjusted earnings per share (EPS) of $2.95, which missed the Zacks Consensus Estimate of $3.16. Earnings declined 27% year over year. On a constant currency basis, earnings were flat.Total revenues came in at $2.39 billion, down 6% on a reported basis (5% on a constant-currency basis) from the year-ago quarter due to lower sales of all key drugs, multiple sclerosis (MS) drugs like Tecfidera and Tysabri as well as spinal muscular atrophy drug, Spinraza. Sales missed ...

Biogen Inc. (BIIB) reported $2.39 billion in revenue for the quarter ended December 2023, representing a year-over-year decline of 6.2%. EPS of $2.95 for the same period compares to $4.05 a year ago.The reported revenue represents a surprise of -2.88% over the Zacks Consensus Estimate of $2.46 billion. With the consensus EPS estimate being $3.16, the EPS surprise was -6.65%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine ...

Biogen Inc. (BIIB) came out with quarterly earnings of $2.95 per share, missing the Zacks Consensus Estimate of $3.16 per share. This compares to earnings of $4.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6.65%. A quarter ago, it was expected that this company would post earnings of $3.99 per share when it actually produced earnings of $4.36, delivering a surprise of 9.27%.Over the last four quarters, the company has s ...

Q4 and Full Year 2023 Financial Results and Business Update Non-GAAP financial information This presentation and the discussions during this conference call include certain financial measures that were not prepared in accordance with accounting principles generally accepted in the U.S. (GAAP), including adjusted net income, adjusted diluted earnings per share, revenue growth at constant currency, which excludes the impact of changes in foreign exchange rates and hedging gains or losses, and free cash flow, ...

Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to dropping its controversial Alzheimer's drug Aduhelm and as sales slumped in its multiple sclerosis therapies, the company's biggest drug category.Biogen booked sales of $2.39 billion for the quarter, down 6% from the same period a year ago. Revenue from multiple sclerosis products fell 8% to $1.17 billion as the therapies face competition from cheaper generics. The results come as the ...

Friedreich's ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorderTreatment with SKYCLARYS improved patient function compared to placeboBiogen is leveraging its expertise and capabilities in rare disease to bring this groundbreaking treatment to patients CAMBRIDGE, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) --  Biogen Inc. (NASDAQ:BIIB) announced the European Commission (EC) has authorized SKYCLARYS® (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in adults and ad ...

We expect Biogen (BIIB) to beat expectations when it reports fourth-quarter and full-year 2023 results on Feb 13, before market open. In the last reported quarter, the company delivered an earnings surprise of 9.27%.Factors to ConsiderBiogen’s sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and rising competitive pressure in the MS market. Tecfidera sales have been declining as multiple generic versions of the drug hav ...

Wall Street analysts expect Biogen Inc. (BIIB) to post quarterly earnings of $3.16 per share in its upcoming report, which indicates a year-over-year decline of 22%. Revenues are expected to be $2.46 billion, down 3.4% from the year-ago quarter.Over the last 30 days, there has been a downward revision of 0.4% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timefram ...

Biogen Inc. (BIIB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 13, 2024, might help the stock move higher if these key numbers are better than ...